Navigation Links
Radient Pharmaceuticals Corporation Joins OTCQX
Date:6/23/2011

NEW YORK, June 23, 2011 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, today announced that Radient Pharmaceuticals Corporation (OTCQX: RXPC), the developer and worldwide marketer of the Onko-Sure® non-invasive cancer blood test kit, has qualified to trade on the OTC market's highest tier, OTCQX®.

(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO)

"Radient Pharmaceuticals has chosen to remain investor-focused as they transition to trade on OTCQX, which allows them to continue to provide superior information and transparent trading on the quality-controlled OTCQX platform," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Radient Pharmaceuticals to OTCQX."

Radient Pharmaceuticals began trading today on the OTC market's prestigious tier, OTCQX U.S. Premier. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcqx.com and www.otcmarkets.com.

"In moving to OTCQX, we will continue to deliver liquidity, transparency, and an efficient market for our shareholders while reducing the financial and management resources required for an exchange listing," Douglas MacLellan, CEO of Radient Pharmaceuticals. "We are moving forward, dedicating more time and resources to the execution of our core business delivering high-value cancer diagnostics to the global healthcare system."

Merriman Capital, Inc. will serve as Radient Pharmaceuticals' Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing guidance on OTCQX requirements.

About Radient Pharmaceuticals

Radient Pharmaceuticals Corporation (OTCQX: RXPC) trades in the United States on OTCQX under the symbol "RXPC". The Company is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks.  Our OTC Link™ platform supports an open network of competing broker-dealers that provide investors with the best prices in over 10,000 OTC securities.  In 2010, securities on OTC Link traded over $144 billion in dollar volume, making it the third largest U.S. equity trading venue after NASDAQ and the New York Stock Exchange. We categorize the wide spectrum of OTC companies into three tiers - OTCQX (the quality-controlled marketplace for investor friendly companies), OTCQB® (the U.S. reporting company marketplace for development stage companies), and OTC Pink™ (the speculative trading marketplace) - so investors can identify the level and quality of information companies provide.  To learn more about how OTC Markets Group makes the unlisted markets more transparent, informed, and efficient, visit www.otcmarkets.com.

Subscribe to the OTCQX RSS Feed


'/>"/>
SOURCE OTC Markets Group Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... be familiar with watching a film or TV show in high definition, you may not ... Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s top brands as ... ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... mark for blood and service orders. Blood suppliers and their hospitals use ... , “BloodHub serves 13,000 active users across 2,100 hospitals who use our platform ...
(Date:5/4/2016)... , ... May 05, 2016 , ... “Less than 15% ... Little City Executive Director. “As one of ten non-profit organizations to participate and complete ... of Light. The ultimate benefit is that for every $1 we invest in volunteer ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... in grants to identify, fund and implement ideas aimed at improving care and ... , “Part of our vision for Trinity Health is to drive innovation ...
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare Systems ... announced it has secured $9 million in Series A funding led by TransLink ... will be used by Somnoware to further fulfill its mission to connect, organize ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
Breaking Medicine News(10 mins):